

### PRIOR AUTHORIZATION REQUEST

# **Radicava**

Patient Informati	on:	
Name:		
Member ID:		
Address:		
City, State, Zip:		
Date of Birth:		
Prescriber Inforr	mation:	
Name:		
NPI:		
Phone Number:		
Fax Number		
Address:		
City, State, Zip:		
•		
Requested Medic	cation	
Rx Name:		
Rx Strength		
Rx Quantity:		
Rx Frequency:		
Rx Route of		
Administration:		
Diagnosis and ICD Code:		
prescribed a medicat quantities can be pro Upon receipt of the	tion for your ovided. Plea e completed	efit requires that we review certain requests for coverage with the prescriber. You have patient that requires Prior Authorization before benefit coverage or coverage of additionalse complete the following questions then fax this form to the toll-free number listed belowed form, prescription benefit coverage will be determined based on the plan's rules at that supporting clinical documentation is required for ALL PA
		sis or indication? Il Sclerosis (ALS) (If checked, go to 2)
[] Aneurys	smal Subara	achnoid Hemorrhage (If checked, no further questions)
[] Myocard	dial Infarctio	on (If checked, no further questions)
[] Radiatio	on-Induced I	Brain Injury (If checked, no further questions)
[] Retinal	Vein Occlus	sion (If checked, no further questions)
[] Sensori	neural Hear	ring Loss (If checked in a further questions)

## PRIOR AUTHORIZATION REQUEST

	[] Stroke (If checked, no further questions)		
	[] Other (If checked, no further questions)		
2	Is the requested medication prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specialized in the treatment of Amyotrophic Lateral Sclerosis (ALS)? [If no, no further questions.]	Yes	No
3	Is the patient currently receiving the requested medication? [If no, skip to question 9.]	Yes	No
4	Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 9.]	Yes	No
5	Does the patient require invasive ventilation? [If yes, no further questions.]	Yes	No
6	Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 8.]	Yes	No
7	According to the prescriber, has the patient continued to benefit from therapy defined as a score of two points or more on each item of the Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale Revised (ALSFRS-R) (for example, has retained most or all activities of daily living)? [No further questions.]	Yes	No
8	Has documentation been provided to confirm that there is clinical response of the patient's improvement/stabilization on treatment from baseline? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
9	According to the prescriber, does the patient have a "definite" or "probable" diagnosis of amyotrophic lateral sclerosis (ALS) based on the application of the E1 Escorial or the revised Airlie House diagnostic criteria? [If no, no further questions.]	Yes	No
10	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
11	Does the patient have a score of two points or more on each item of the amyotrophic lateral sclerosis (ALS) Functional Rating Scale Revised (ALSFRS-R) (for example, has retained most or all activities of daily living)? [If no, no further questions.]	Yes	No



#### PRIOR AUTHORIZATION REQUEST

12	Does the patient have a percent-predicted forced vital capacity (FVC) GREATER THAN OR EQUAL TO 80 percent (for example, has normal respiratory function)? [If no, no further questions.]	Yes	No
13	Is the patient dependent on invasive ventilation or tracheostomy? [If yes, no further questions.]	Yes	No
14	Has the patient been diagnosed with amyotrophic lateral sclerosis (ALS) for LESS THAN OR EQUAL TO 2 years? [If no, no further questions.]	Yes	No
15	Is the patient currently receiving riluzole tablets, Tiglutik (riluzole oral suspension), or Exservan (riluzole oral film)? [If no, no further questions.]	Yes	No
16	Does the dose of the requested medication exceed Food and Drug Administration (FDA) approved label dosing for indication?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

### **FAX COMPLETED FORM TO: 1-833-896-0656**

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250